Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bilastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 12/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bilastine SCHEMBL29402994 | 1.00 | HRH1 (0.82) | HRH1KCNH2CYP2D6KDM4EUSP2 | |
| Bilastine SCHEMBL21815518 | 0.97 | HRH1 (0.77) | HRH1KCNH2CYP2D6KDM4E | |
| SCHEMBL30307024 | 0.92 | HRH1 (0.79) | HRH1KCNH2CYP2D6KDM4E | |
| SCHEMBL29506217 | 0.92 | HRH1 (0.79) | HRH1KCNH2CYP2D6 | |
| SCHEMBL991771 | 0.92 | HRH1 (0.79) | HRH1KCNH2CYP2D6KDM4E | |
| SCHEMBL3793927 | 0.92 | HRH1 (0.79) | HRH1KCNH2CYP2D6 | |
| SCHEMBL18884525 | 0.91 | HRH1 (0.68) | HRH1KCNH2CYP2D6USP2POLB | |
| SCHEMBL28422609 | 0.91 | HRH1 (0.75) | HRH1KCNH2CYP2D6KDM4EUSP2 | |
| Alinastine SCHEMBL142547 | 0.90 | HRH1 (1.00) | HRH1KCNH2 | |
| SCHEMBL4707799 | 0.89 | HRH1 (0.83) | HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107365297-B | Preparation method and intermediate of 2-methyl-2' -phenylpropionic acid derivative | 罗欣药业(上海)有限公司 | 2020-07-03 | — | — | CN | claimed |
| EP-3452462-A1 | SOLID STATE FORMS OF 2-[4-(2-{4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL}ETHYL)PHENYL]-2-METHYLPROPANOIC ACID AND PROCESS FOR PREPARATION THEREOF | MSN Laboratories Private Limited, R&D Center (IN) | 2019-03-13 | — | — | EP | claimed |
| WO-2017191651-A1 | SOLID STATE FORMS OF 2-[4-(2-{4-[1-(2-ETHOXYETHYL)-1H-BENZIMIDAZOL-2-YL]-1-PIPERIDINYL}ETHYL)PHENYL]-2-METHYLPROPANOIC ACID AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED, R & D CENTER (IN) | 2017-11-09 | — | — | WO | claimed |
| US-8367704-B2 | Process for preparation of 2-methyl-2′ phenylpropionic acid derivatives and novel intermediate compounds | YUHAN CORPORATION (KR) | 2013-02-05 | — | — | US | claimed |
| US-20110009636-A1 | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KP) | 2011-01-13 | — | — | US | claimed |
| EP-2240464-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | Yuhan Corporation (KR) | 2010-10-20 | — | — | EP | claimed |
| WO-2009102155-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2009-08-20 | — | — | WO | claimed |
| EP-0818454-B1 | Benzimidazole derivatives with antihistaminic activity | ESPANOLA DE PRODUCTOSQUIMICOS (ES) | 2004-04-14 | — | — | EP | claimed |
| EP-0818454-A1 | Benzimidazole derivatives with antihistaminic activity | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1998-01-14 | — | — | EP | claimed |
| US-20260109705-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2026-04-23 | — | — | US | disclosed |
| EP-4479048-B1 | BILASTINE COMPOSITION FOR ONCE-DAILY PARENTERAL ADMINISTRATION | FAES FARMA SA (ES) | 2026-03-18 | — | — | EP | disclosed |
| US-20260027099-A1 | OPHTHALMIC COMPOSITIONS COMPRISING BILASTINE, A BETA-CYCLODEXTRIN AND AT LEAST ONE GELLING AGENT | FAES FARMA SA (ES) | 2026-01-29 | — | — | US | disclosed |
| EP-4637713-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2025-10-29 | — | — | EP | disclosed |
| US-20250228836-A1 | BILASTINE COMPOSITION FOR ONCE-DAILY PARENTERAL ADMINISTRATION | FAES FARMA, S.A. (ES) | 2025-07-17 | — | — | US | disclosed |
| US-20060018867-A1 | Cosmetic composition and production thereof | ICHIMARU PHARCOS CO., LTD | 2006-01-26 | — | — | US | disclosed |
| EP-1604647-A1 | Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof | Ichimaru Pharcos Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| EP-0818454-B1 | Benzimidazole derivatives with antihistaminic activity | ESPANOLA DE PRODUCTOSQUIMICOS (ES) | 2004-04-14 | — | — | EP | disclosed |
| US-5877187-A | Benzimidazole derivatives with antihistaminic activity | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (FAES) (ES) | 1999-03-02 | — | — | US | disclosed |
| EP-0818454-A1 | Benzimidazole derivatives with antihistaminic activity | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1998-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009636-A1 | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH4, HCAR2, HRH1 | HRH1 3/4885KCNH2 945/4885CYP2D6 231/4885 |
| US-20260109705-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | DSG1, HRH2, H1-2 | HRH1 5/4885KCNH2 1053/4885CYP2D6 825/4885 |
| US-20260027099-A1 | OPHTHALMIC COMPOSITIONS COMPRISING BILASTINE, A BETA-CYCLODEXTRIN AND AT LEAST ONE GELLING AGENT | HRH1, HRH3, HRH2 | HRH1 1/4885KCNH2 1936/4885CYP2D6 134/4885 |
| US-20250228836-A1 | BILASTINE COMPOSITION FOR ONCE-DAILY PARENTERAL ADMINISTRATION | HRH4, HRH1, HRH2 | HRH1 2/4885KCNH2 147/4885CYP2D6 29/4885 |
| US-20060018867-A1 | Cosmetic composition and production thereof | CUTA, PARG, TYR | HRH1 712/4885KCNH2 1552/4885CYP2D6 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.